Moneycontrol
HomeNewsTrendsHealthSouth Africa to pay $5.25 a dose for AstraZeneca vaccine from India's Serum Institute of India
Trending Topics

South Africa to pay $5.25 a dose for AstraZeneca vaccine from India's Serum Institute of India

The price is higher than the $3 a dose that South Africa and other countries on the continent are due to pay for the same vaccines under an African Union (AU) arrangement, and the price European Union countries have agreed to pay.

January 21, 2021 / 17:29 IST
Story continues below Advertisement

South Africa will pay $5.25 per dose for 1.5 million shots of AstraZeneca’s COVID-19 vaccine from the Serum Institute of India (SII), a senior health ministry official said on Thursday, more than some wealthier countries are paying.
The price is higher than the $3 a dose that South Africa and other countries on the continent are due to pay for the same vaccines under an African Union (AU) arrangement, and the price European Union countries have agreed to pay.

The SII doses are intended for South Africa’s frontline healthcare workers, who have been under huge strain during a second wave of coronavirus infections. They are due to start arriving before the end of the month, before the AU doses become available from March.

Story continues below Advertisement

Follow our LIVE blog for latest updates of the novel coronavirus pandemic
The SII declined to comment when contacted by Reuters. AstraZeneca did not immediately respond to a request for comment.

Health department Deputy Director-General Anban Pillay said SII’s price for South Africa was based on the country’s status as an upper-middle-income level country, confirming a report in the Business Day newspaper.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show